We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

187 hedge funds and large institutions have $2.72B invested in Intra-Cellular Therapies Inc. in 2021 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 68 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more call options, than puts

Call options by funds: $39M | Put options by funds: $11.4M

121% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

18% more capital invested

Capital invested by funds: $2.3B → $2.72B (+$423M)

10% more funds holding

Funds holding: 170 → 187 (+17)

16% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 68

Holders
187
Holders Change
+17
Holders Change %
+10%
% of All Funds
3.26%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
31
Increased
57
Reduced
68
Closed
14
Calls
$39M
Puts
$11.4M
Net Calls
+$27.6M
Net Calls Change
+$23.2M

Top Buyers

Rank Fund Capital Flow
1
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
+$9.86M
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$9.71M
3
Morgan Stanley
Morgan Stanley
New York
+$8.32M
4
Franklin Resources
Franklin Resources
California
+$7.25M
5
BGIM
Brandywine Global Investment Management
Pennsylvania
+$7.23M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$16.2M
2
SI
Sofinnova Investments
California
-$12.6M
3
WP
Woodline Partners
California
-$9.98M
4
SC
Samlyn Capital
New York
-$8.94M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
76
First Trust Advisors
Illinois
$2.12M +$1.92M +52,003 New
Citigroup
77
Citigroup
New York
$2.01M +$593K +16,046 +48%
EI
78
EAM Investors
California
$1.97M +$1.78M +48,220 New
D.E. Shaw & Co
79
D.E. Shaw & Co
New York
$1.96M -$2.66M -71,936 -60%
CS
80
Credit Suisse
Switzerland
$1.95M -$162K -4,393 -8%
Legal & General Group
81
Legal & General Group
United Kingdom
$1.91M +$1.07K +29 +0.1%
SEI Investments
82
SEI Investments
Pennsylvania
$1.89M +$1.06M +28,738 +164%
PAM
83
Premier Asset Management
Illinois
$1.74M +$1.11M +30,152 +242%
Stifel Financial
84
Stifel Financial
Missouri
$1.62M -$16K -433 -1%
BFM
85
Boothbay Fund Management
New York
$1.59M – – –
Manulife (Manufacturers Life Insurance)
86
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.56M +$85.8K +2,322 +6%
T. Rowe Price Associates
87
T. Rowe Price Associates
Maryland
$1.48M -$150K -4,046 -10%
ProShare Advisors
88
ProShare Advisors
Maryland
$1.34M +$148K +4,000 +14%
HSA
89
Hussman Strategic Advisors
Maryland
$1.26M +$1.15M +31,000 New
Principal Financial Group
90
Principal Financial Group
Iowa
$1.22M +$198K +5,364 +22%
DekaBank Deutsche Girozentrale
91
DekaBank Deutsche Girozentrale
Germany
$1.21M – – –
VOYA Investment Management
92
VOYA Investment Management
Georgia
$1.14M -$57.1K -1,544 -5%
EGM
93
Engineers Gate Manager
New York
$1.14M +$1.03M +27,816 New
State Board of Administration of Florida Retirement System
94
State Board of Administration of Florida Retirement System
Florida
$1.11M +$54.9K +1,485 +6%
MIM
95
MetLife Investment Management
New Jersey
$1.08M – – –
AC
96
Avestar Capital
New York
$1.06M +$176K +4,774 +22%
SG
97
Stonnington Group
California
$1.03M +$943K +25,500 New
WMSA
98
Weiss Multi-Strategy Advisers
New York
$849K +$27.4K +742 +4%
EAM
99
Erste Asset Management
Austria
$835K – – –
SG Americas Securities
100
SG Americas Securities
New York
$833K +$203K +5,488 +37%
2 3
4
5 6

ITCI Hedge Fund Activity: Q2 2021 in Review

187 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2021, worth a combined $2.72B — up 18% from $2.3B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ITCI positions and 14 closed out — a net gain of 17 holders — while 57 added to existing stakes and 68 trimmed.

The largest buyer was Skandinaviska Enskilda Banken (SEB), adding an estimated $9.86M. The largest seller was BlackRock, cutting an estimated $16.2M.

  • 187 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2021, up from 170 in Q1 2021.
  • Funds reported $2.72B of Intra-Cellular Therapies Inc. stock for Q2 2021, up 18% quarter-over-quarter.
  • 31 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2021 and 14 closed out, a net change of +17 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2021 was Skandinaviska Enskilda Banken (SEB), an estimated $9.86M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2021 was BlackRock, an estimated $16.2M sold.

Based on aggregated 13F filings for Q2 2021.